Provided by Tiger Trade Technology Pte. Ltd.

PEGBIO CO-B

5.620
+0.0400.72%
Volume:5.84M
Turnover:32.89M
Market Cap:2.20B
PE:-8.75
High:5.845
Open:5.630
Low:5.450
Close:5.580
52wk High:77.000
52wk Low:4.940
Shares:391.00M
HK Float Shares:386.00M
Volume Ratio:0.76
T/O Rate:1.51%
Dividend:- -
Dividend Rate:- -
EPS(LYR):-0.642
ROE:-125.57%
ROA:-44.55%
PB:7.05
PE(LYR):-8.75
PS:-164.34

Loading ...

Registration Open for "Zhihui Financial 2026 Summer Roadshow Conference"

Stock News
·
May 18

PegBio Reports No Share Capital Changes in April 2026; Public Float Remains Compliant

Bulletin Express
·
May 06

Stock Track | PEGBIO CO-B Soars 18.91% Intraday as Cornerstone Investors Extend Lock-Up Period, Signaling Strong Confidence

Stock Track
·
May 05

PEGBIO Shares Surge Nearly 19% on Extended Lock-Up Period Demonstrating Long-Term Confidence

Stock News
·
May 05

Stock Track | PEGBIO CO-B Soars 10.69% Intraday on Lock-Up Extension and Clinical Milestone

Stock Track
·
Apr 29

PEGBIO CO-B Shares Surge Over 11% to HK$29.32 as Cornerstone Investors Extend Lock-Up Period

Stock News
·
Apr 29

PEGBIO CO-B 2025年净亏损收窄至2.085亿元,「Paidakang®」完成上市审批

Bulletin Express
·
Apr 28

Pegbio publishes 2025 annual report

Reuters
·
Apr 28

PegBio cornerstone investor holds 9,584,500 H shares, or 3.37% of H-share capital

Reuters
·
Apr 28

PegBio: Cornerstone Investor Extends Lock-Up on 9.58 Million H Shares to 20 May 2026

Bulletin Express
·
Apr 28

PegBio Wins China Nod for Hong Kong Share Full Circulation

MT Newswires Live
·
Apr 10

PegBio Receives CSRC Filing Notice for Conversion of 101.70 Million Unlisted Shares to H Shares

Bulletin Express
·
Apr 09

PEGBIO CO-B Receives CSRC Filing Notice for H-Share Full Circulation

Stock News
·
Apr 09

PegBio receives CSRC filing notice for H-share full circulation of 101,702,051 shares

Reuters
·
Apr 09

PegBio Reports No Share Capital Changes, Confirms Public Float Compliance for March 2026

Bulletin Express
·
Apr 08

PegBio's CR059 Selection for ADA Late-Breaking Abstract Highlights Monthly-Dosing GLP-1 Potential

Stock News
·
Apr 07

PegBio's CR059, a Potential Game-Changer in Metabolic Disease Treatment, Garners Prestigious Recognition at ADA Conference

Stock News
·
Apr 02

PegBio Announces ADA 2026 Late-Breaking Abstract Acceptance for Once-Monthly GLP-1 Candidate CR059

Bulletin Express
·
Apr 02

PEGBIO CO-B's CR059 Research Abstract Accepted for Poster Presentation at ADA 2026 Scientific Sessions

Stock News
·
Apr 02

PegBio says CR059 diabetes abstract accepted as ADA late-breaking poster presentation

Reuters
·
Apr 02